Literature DB >> 641810

Hydrolysis and protein binding of melphalan.

S Y Chang, D S Alberts, D Farquhar, L R Melnick, P D Walson, S E Salmon.   

Abstract

Melphalan (30 microgram/ml) is completely hydrolyzed in water at 37 degrees after 8 hr. At lower temperatures, hydrolysis proceeds at slower rates. The presence of bovine serum albumin retards hydrolysis of melphalan (30 microgram/ml) in water. The melphalan hydrolysis rate is directely releated to the bovine serum albumin concentration. At 37 degrees, 8 g of bovine serum albumin/100 ml of water gives a recovery rate of melphalan similar to that of human plasma. In vitro alkylation of melphalan at 37 degrees with human plasma containing 30 microgram/ml, calculated by equilibrium dialysis, methanol extraction, and high-pressure liquid chromatographic analysis, is 30% after 8 hr.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 641810     DOI: 10.1002/jps.2600670530

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

1.  Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.

Authors:  S Gera; E Musch; H K Osterheld; U Loos
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Authors:  Christa E Nath; Peter J Shaw; Judith Trotman; Lihua Zeng; Stephen B Duffull; Gareth Hegarty; Andrew J McLachlan; Howard Gurney; Ian Kerridge; Yiu Lam Kwan; Peter Presgrave; Campbell Tiley; Douglas Joshua; John Earl
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

3.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits.

Authors:  I A Taha; R A Ahmad; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Concentration profile for the dissolution of drug tablets undergoing simultaneous degradation.

Authors:  H S Chen; S Y Chang; T L Evans; J F Gross
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

6.  Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.

Authors:  Christa E Nath; Peter J Shaw; Kay Montgomery; John W Earl
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

7.  Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Authors:  S Y Lee; R S Meehan; D C Seldin; J M Sloan; K Quillen; A Shelton; D Brauneis; V Sanchorawala
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

8.  Pharmacokinetics of high-dose melphalan in children and adults.

Authors:  A Gouyette; O Hartmann; J L Pico
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  In vitro degradation of L-phenylalanine mustard (L-PAM).

Authors:  T L Evans; S Y Chang; D S Alberts; I G Sipes; K Brendel
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.